1. Home
  2. GH vs ABTC Comparison

GH vs ABTC Comparison

Compare GH & ABTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • ABTC
  • Stock Information
  • Founded
  • GH 2011
  • ABTC 2024
  • Country
  • GH United States
  • ABTC United States
  • Employees
  • GH N/A
  • ABTC N/A
  • Industry
  • GH Medical Specialities
  • ABTC EDP Services
  • Sector
  • GH Health Care
  • ABTC Technology
  • Exchange
  • GH Nasdaq
  • ABTC Nasdaq
  • Market Cap
  • GH 4.9B
  • ABTC 4.2B
  • IPO Year
  • GH 2018
  • ABTC N/A
  • Fundamental
  • Price
  • GH $98.28
  • ABTC $4.90
  • Analyst Decision
  • GH Strong Buy
  • ABTC
  • Analyst Count
  • GH 22
  • ABTC 0
  • Target Price
  • GH $74.32
  • ABTC N/A
  • AVG Volume (30 Days)
  • GH 3.4M
  • ABTC 2.6M
  • Earning Date
  • GH 10-29-2025
  • ABTC 11-14-2025
  • Dividend Yield
  • GH N/A
  • ABTC N/A
  • EPS Growth
  • GH N/A
  • ABTC N/A
  • EPS
  • GH N/A
  • ABTC 2.64
  • Revenue
  • GH $902,569,000.00
  • ABTC $69,890,000.00
  • Revenue This Year
  • GH $33.95
  • ABTC N/A
  • Revenue Next Year
  • GH $25.77
  • ABTC N/A
  • P/E Ratio
  • GH N/A
  • ABTC $1.76
  • Revenue Growth
  • GH 30.38
  • ABTC 6.38
  • 52 Week Low
  • GH $28.45
  • ABTC $4.08
  • 52 Week High
  • GH $101.57
  • ABTC $14.52
  • Technical
  • Relative Strength Index (RSI)
  • GH 77.88
  • ABTC N/A
  • Support Level
  • GH $88.88
  • ABTC N/A
  • Resistance Level
  • GH $97.51
  • ABTC N/A
  • Average True Range (ATR)
  • GH 4.94
  • ABTC 0.00
  • MACD
  • GH 1.89
  • ABTC 0.00
  • Stochastic Oscillator
  • GH 88.05
  • ABTC 0.00

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About ABTC American Bitcoin Corp. Class A Common Stock

American Bitcoin Corp is a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure platform. The Company delivers institutional-grade exposure to Bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies.

Share on Social Networks: